Results 1 to 10 of about 59,004 (282)
Trial of Intravenous Immune Globulin in Dermatomyositis
New England Journal of Medicine, 2022 BACKGROUND Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated. METHODS We conducted a randomized, placebo-controlled trial involving patients with active dermatomyositis.
Rohit Aggarwal +2 more
exaly +2 more sources
Dermatomyositis: Practical Guidance and Unmet Needs
ImmunoTargets and TherapyLydia Cassard,1 Noelle Seraly,2 Maureen Riegert,3 Aditi Patel,4 Anthony P Fernandez5 1Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, USA; 2Department of Dermatology, Cleveland Clinic, Cleveland, OH, USA ...
Cassard L +4 more
doaj +2 more sources
Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease
New England Journal of Medicine, 2019 Amyopathic Dermatomyositis–Related Lung Disease The autoimmune disease amyopathic dermatomyositis–associated interstitial lung disease, which is related to anti–melanoma differentiation–associated ...
Zhiwei Chen, Xiaodong Wang
exaly +2 more sources
Paraneoplastic dermatomyositis with Kaposi’s sarcoma: A case report [PDF]
SAGE Open Medical Case ReportsDermatomyositis is a rare autoimmune condition known to be frequently associated with an undiagnosed malignancy. Although it is strongly linked to adenocarcinomas and other solid tumors, dermatomyositis has been scarcely described with sarcomas.
Shu Yu Qian +2 more
doaj +2 more sources
Acta Dermato-Venereologica, 2018 Anti-transcriptional intermediary factor-1γ (TIF-1γ) autoantibody may be associated with cancer in adult patients with dermatomyositis. The aim of this study was to evaluate the risk of cancer in the presence of anti-TIF-1γ autoantibody in adult ...
Marion Best +5 more
doaj +2 more sources
Trigeminal involvement in dermatomyositis with double positivity for anti-transcriptional intermediary factor 1 gamma and anti-Ku antibodies: A case report and literature review [PDF]
Journal of International Medical ResearchAnti-transcriptional intermediary factor 1 gamma antibody and anti-Ku antibody double-positive dermatomyositis and trigeminal neuropathy involvement are often regarded as clinically distinct diseases with differing pathogenesis. Herein, we present a rare
Sun Yingchao +5 more
doaj +2 more sources
Research progress on risk factors for dermatomyositis with malignancy
Pifu-xingbing zhenliaoxue zazhi, 2023 Malignant tumors are one of the major causes of mortality in patients with dermatomyositis. But the majority of these tumors are diagnosed after the diagnosis of dermatomyositis. Because the timing of diagnosis of tumor is associated with the survival of
Juanjuan PAN, Jing WANG, Guozhen TAN
doaj +1 more source
Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies
Frontiers in Immunology, 2021 Anti-MDA5 dermatomyositis is a rare systemic autoimmune disease, historically described in Japanese patients with clinically amyopathic dermatomyositis and life-threatening rapidly progressive interstitial lung disease.
Anaïs Nombel, N. Fabien, F. Coutant
semanticscholar +1 more source
Paraneoplastic Wong-Type Dermatomyositis Associated with Gynecological Malignancy
Medicina, 2022 Although dermatomyositis is known to be a possible paraneoplastic syndrome, often in the setting of gynecological cancers, Wong-type dermatomyositis—a rare variant of dermatomyositis—has not been clearly associated with internal malignancies to date ...
Roberto Russo +4 more
doaj +1 more source
Enhanced immune complex formation in the lungs of patients with dermatomyositis
Respiratory Research, 2023 Background Interstitial lung disease is frequently comorbid with dermatomyositis and has a poor prognosis, especially in patients with the anti-melanoma differentiation-associated gene 5 (MDA5) autoantibody.
Yoshiaki Zaizen +8 more
semanticscholar +1 more source